Followers | 28 |
Posts | 1197 |
Boards Moderated | 0 |
Alias Born | 05/14/2014 |
![](https://investorshub.advfn.com/uicon/478670.png?cb=1475601573)
Tuesday, October 18, 2016 10:43:58 AM
"In July 2016 the Globe and Mail conducted an investigation into contamination in cannabis after purchasing products from nine storefronts in Toronto. Their research team found that one-third of the samples would not pass a Health Canada safety test. Three of the nine samples contained excessively high levels of bacteria and one not only contained mold but yeast at concentrations that could cause serious lung conditions.
Surprisingly, the Controlled Drugs and Substances Act prevented government-approved cannabis testing facilities from possessing any amount of the drug brought in by the public. With hundreds of illegal dispensaries operating outside of the MMPR program, this meant that consumers had no way of knowing if their product was safe."
So, 3/9 of the samples posed a noteworthy risk to consumers, 1 was downright dangerous, and there's potentially hundreds of dispensaries that could be exposing consumers to these risks.
Is testing important? Hmm you tell me.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM